Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD

February 2, 2023

https://www.globenewswire.com/news-release/2023/02/02/2600340/0/en/Clearside-Biomedical-Announces-Positive-6-Month-Results-from-OASIS-Extension-Study-with-Suprachoroidal-CLS-AX-axitinib-injectable-suspension-in-Wet-AMD.html

– Suprachoroidal CLS-AX Resulted in Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders –

– 67% of Extension Study Participants Went at Least 6 Months Without Needing Additional Treatment –

Read more at globenewswire.com

Related news for (CLSD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.